BriaCell Therapeutics Corp. (BCTX)
| Market Cap | 20.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 6.70M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 21 |
| Last Price | $3.03 |
| Previous Close | $2.89 |
| Change ($) | 0.14 |
| Change (%) | 4.84% |
| Day's Open | 2.85 |
| Day's Range | 2.84 - 3.08 |
| Day's Volume | 520,238 |
| 52-Week Range | 0.00 - 3.08 |
BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotech...
BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotech...
BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced the presentation of results from clinical studies evaluating its lead product candidate, Bria-IMT, at the American Association for Cancer Research...
Clinical and pathological data presented from the clinical trials of Bria-IMT™ alone and in combination with immune checkpoint inhibitors in advanced breast cancer indicates high responding subset with ...
BriaCell Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2021
BERKELEY, Calif. and VANCOUVER, British Columbia, March 30, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotech...
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechn...
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”), a clinical-stage biotechn...
Clinical and pathological findings presented from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer:
BERKELEY, Calif. and VANCOUVER, British Columbia, Jan. 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V: BCT ) (OTCQB:BCTXF), a clinical-stage biotechnology ...
About BCTX
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics... [Read more...]
| Industry Biotechnology | Founded 2014 |
| Stock Exchange NASDAQ | Ticker Symbol BCTX |